{"id":"continue-on-current-dual-boosted-pi","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)"},{"rate":"30-50","effect":"Lipid abnormalities (elevated cholesterol and triglycerides)"},{"rate":"10-20","effect":"Hyperglycemia"},{"rate":"variable","effect":"Lipodystrophy"},{"rate":"5-15","effect":"Hepatotoxicity"},{"rate":"10-20","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Protease inhibitors (PIs) are antiretroviral drugs that inhibit HIV protease, an enzyme essential for processing viral polyproteins into functional components. Dual boosting typically involves combining a primary PI with a pharmacokinetic booster (such as ritonavir or cobicistat) to increase the primary PI's plasma concentration and half-life, improving efficacy and allowing for lower dosing. This combination is a standard component of modern antiretroviral therapy regimens for HIV management.","oneSentence":"Dual-boosted protease inhibitors block HIV protease to prevent viral replication and reduce viral load in HIV-infected patients.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:43:47.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (as part of combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT00543101","phase":"PHASE4","title":"Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2007-10","conditions":"HIV Infections","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"continue on current dual boosted PI","genericName":"continue on current dual boosted PI","companyName":"Community Research Initiative of New England","companyId":"community-research-initiative-of-new-england","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dual boosted PI, specifically Darunavir (DRV/r), has been studied in combination with 3TC for the treatment of HIV Infections and HBV Coinfection. This combination has been evaluated in clinical trials, such as NCT06338826, for its safety and efficacy in controlling HBV virus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}